• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[慢性肾脏病:治疗与护理]

[Chronic kidney disease: therapy and care].

作者信息

Noel Natacha, Gaha Khaled, Rieu Philippe

机构信息

Service de néphrologie, CHU de Reims, hôpital Robert Debré, 51090 Reims Cedex.

出版信息

Rev Prat. 2012 Jan;62(1):43-51.

PMID:22335066
Abstract

Chronic kidney disease (CKD) is a major public health problem. It is therefore important to slow its progression and to treat its complications. Regardless of the causal nephropathy, arterial hypertension and proteinuria are the major progression factors of CKD. Thus, optimal control of blood pressure, reduction of proteinuria by using rennin angiotension system inhibitors can slow the progression of CKD. This effect can be enhanced by reducing sodium intake. The recent recommendations suggest that blood pressure should not be higher than 130/80 mmHg and proteinuria should not exceed 0,5 g/day. The consequences of advanced stages of the CKD have to be diagnosed and treated early: anemia, abnormal bone metabolism, hyperkalemia, fluid overload, metabolic acidosis... A particular emphasis has to be given to cardiovascular complications and risk factors. Monitoring data are well defined by the actual recommandations. Nephrologist can provide a set of recommended intervention to the primary care physician. The most accepted criterion of initiation of dialysis, in absence of clinic uremic manifestation is a glomerular filtration rate lower than 7 ml/min/1,73m2. Psychological and medical preparation of the patient to dialysis is essential. The possibility of renal transplantation should be evaluated during the following of patient with CKD

摘要

慢性肾脏病(CKD)是一个重大的公共卫生问题。因此,减缓其进展并治疗其并发症很重要。无论病因性肾病如何,动脉高血压和蛋白尿都是CKD的主要进展因素。因此,通过使用肾素血管紧张素系统抑制剂来优化血压控制、减少蛋白尿,可以减缓CKD的进展。减少钠摄入可增强这种效果。最近的建议表明,血压不应高于130/80 mmHg,蛋白尿不应超过0.5 g/天。CKD晚期的后果必须尽早诊断和治疗:贫血、骨代谢异常、高钾血症、液体过载、代谢性酸中毒……必须特别重视心血管并发症和危险因素。监测数据由现行建议明确界定。肾病科医生可以向初级保健医生提供一系列推荐的干预措施。在没有临床尿毒症表现的情况下,最被认可的开始透析的标准是肾小球滤过率低于7 ml/min/1.73m²。患者对透析的心理和医疗准备至关重要。对于CKD患者,应在随访期间评估肾移植的可能性。

相似文献

1
[Chronic kidney disease: therapy and care].[慢性肾脏病:治疗与护理]
Rev Prat. 2012 Jan;62(1):43-51.
2
Treatment of hypertension in chronic kidney disease.慢性肾脏病高血压的治疗
Semin Nephrol. 2005 Nov;25(6):435-9. doi: 10.1016/j.semnephrol.2005.05.016.
3
[Electrolyte and acid-base balance disorders in advanced chronic kidney disease].[晚期慢性肾脏病中的电解质和酸碱平衡紊乱]
Nefrologia. 2008;28 Suppl 3:87-93.
4
Strict blood-pressure control and progression of renal failure in children.儿童严格血压控制与肾衰竭进展
N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.
5
[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].[慢性肾脏病(CKD)患者的动脉高血压和血脂异常。抗血小板聚集。目标导向治疗]
Nefrologia. 2008;28 Suppl 3:39-48.
6
Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.在南加州凯撒医疗机构实施美国肾脏病预后质量倡议(KDOQI)的慢性肾脏病(CKD)定义及分期指南。
Am J Kidney Dis. 2009 Mar;53(3 Suppl 3):S86-99. doi: 10.1053/j.ajkd.2008.07.052.
7
Identification and management of chronic kidney disease complications by internal medicine residents: a national survey.内科住院医师对慢性肾脏病并发症的识别和管理:一项全国性调查。
Am J Ther. 2011 May;18(3):e40-7. doi: 10.1097/MJT.0b013e3181bbf6fc.
8
[Epidemiology of chronic kidney disease].[慢性肾脏病流行病学]
Rev Prat. 2012 Jan;62(1):38-42.
9
Improving the management of chronic kidney disease in Uruguay: a National Renal Healthcare Program.改善乌拉圭的慢性肾脏病管理:国家肾脏保健计划。
Nephron Clin Pract. 2010;114(1):c47-59. doi: 10.1159/000245069. Epub 2009 Oct 9.
10
Complications of progression of CKD.慢性肾脏病进展的并发症。
Adv Chronic Kidney Dis. 2011 Nov;18(6):400-5. doi: 10.1053/j.ackd.2011.10.001.